Oncolytics Biotech Inc

Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent for cancer. The company is organized around advancing this oncology program through clinical development, manufacturing readiness, and regulatory submission activities.

1.12

1.12

— Oncolytics Biotech Inc
%
Pelareorep clinical development70% Development of pelareorep as an intravenously delivered cancer immunotherapy.
Manufacturing and process development20% Drug substance, fill-finish, analytical testing, and process validation activities.
Regulatory and translational support10% Work supporting clinical trials, regulatory filings, and biomarker/translation efforts.

Oncolytics does not sell a commercial product to end consumers; its primary counterparties are clinical investigators,...

  • Clinical trial investigators and sitesprimary

    They use pelareorep in sponsored studies to generate efficacy and safety data.

  • Regulatory authoritiesprimary

    They review clinical, manufacturing, and quality data for approval pathways.

  • Contract manufacturing organizationssecondary

    They produce drug substance and finished product under cGMP conditions.

  • Strategic collaborators and licenseessecondary

    They may fund development or commercialize pelareorep in defined indications.

  • Future oncology treatment providersemerging

    If approved, hospitals and cancer centers would administer pelareorep-based therapy.

The company is headquartered in the United States and reports in U.S. dollars, while its operating footprint is tied to...

  • •Headquartered in the United States
  • •Clinical development and regulatory work are U.S.-centric
  • •Manufacturing and supply chain activities may involve third-party sites
  • •No commercial revenue geography disclosed
  • •Geographic exposure is driven by trial and manufacturing execution

The company’s strategy is to advance pelareorep through clinical development, with emphasis on metastatic colorectal...

01
Advance key oncology indicationsshort-term

Clinical progress in lead tumor types is the main value driver for a single-asset biotech.

02
Complete manufacturing validationshort-term

Process validation and cGMP readiness are required for regulatory submission and future supply.

03
Secure external funding and partnershipsshort-term

Development-stage biotech programs require ongoing capital and may benefit from shared risk.

Oncolytics faces the typical risks of a clinical-stage biotech: clinical trial failure, regulatory delay, and...

critical

Clinical development failure

Pelareorep must show sufficient safety and efficacy in oncology trials to support approval.

Scope
Lead programs in metastatic colorectal cancer and anal canal cancer
Materiality
high
high

Financing and dilution risk

The company expects to rely on equity or collaborations to fund operations.

Scope
ATM offerings, strategic collaborations, licensing
Materiality
high
high

Manufacturing and process validation risk

Commercial readiness depends on successful cGMP production and validated processes.

Scope
Drug substance, fill-finish, process performance qualification
Materiality
high
high

Regulatory approval risk

Even positive clinical data must satisfy FDA and other regulators on quality and efficacy.

Scope
Submission package and approval pathway
Materiality
high
Research and development accruals
Can cause quarter-to-quarter expense volatility
Equity financing and share issuance
Changes share count and financing-related disclosures
Stock-based compensation
Non-cash expense affects operating loss and diluted share metrics
Functional currency change
Affects translation of foreign-currency balances and comparability
Lease and contractual obligations
Influences liabilities and near-term cash needs

Onconetix, Inc.

ONCO · Pharmaceutical Preparations

CG Oncology, Inc.

CGON · Biological Products, (No Diagnostic Substances)

Moleculin Biotech, Inc.

MBRX · Pharmaceutical Preparations

Oncotelic Therapeutics, Inc.

OTLC · Pharmaceutical Preparations

PharmaCyte Biotech, Inc.

PMCB · Biological Products, (No Diagnostic Substances)

Lundbergföretagen

LUND-B.ST · Financials

: 16.6.2026